Maccura Biotechnology: 2020 net profit about 795 million yuan, an increase of 51.43% YoY
NBD AI Bulletin -- Maccura Biotechnology Co., Ltd (SZ 300463, close price: 40.17 Yuan) released the 2020 annual results briefings on February 25, saying that the Company recorded gross revenue of about 3.704 billion yuan, an increase of 14.91% from a year earlier, the net profit attributable to shareholders amounted to about 795 million yuan, up 51.43% year over year and the basic earnings per share stood at 1.4303 yuan, up 50.65% compared with the previous year.
The 2019 annual report shows that Maccura Biotechnology's main business is in vitro diagnosis, accounting for 100.0% of revenue.
Maccura Biotechnology's chairman is Tang Yong, male, 58 years old, Chinese national, no permanent overseas residency, bachelor's degree. Maccura Biotechnology's general manager is Wu Mingjian, male, 46 years old, Chinese national, no overseas permanent residence, master's degree, senior accountant.
(By Gao Han)
Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.